Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thyrotropin alfa

Drug Profile

Thyrotropin alfa

Alternative Names: MRrhTSH; Recombinant human thyroid stimulating hormone; rhTSH; rhTSH-M; Thyrogen; Thyrotrophin alpha; Thyrotropin; Thyrotropin alpha for injection

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Genzyme Corporation; Odense University Hospital; Sanofi Genzyme
  • Class Diagnostic agents; Pituitary gonadotropins
  • Mechanism of Action Thyrotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thyroid cancer
  • Discontinued Goitre

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 13 May 2015 Discontinued - Phase-II for Goitre in Brazil, Canada, Denmark, France, Germany, Italy and Netherlands (IM, controlled-release)
  • 13 May 2015 Discontinued - Phase-II for Goitre in Denmark (IM, immediate-release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top